ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)

Trial Profile

ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Amantadine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Registrational; Therapeutic Use
  • Acronyms EASE LID 3
  • Sponsors Adamas Pharmaceuticals
  • Most Recent Events

    • 12 Apr 2018 According to an Adamas Pharmaceuticals media release, data from this study will be presented at the 70th Annual Meeting of the American Academy of Neurology (AAN)
    • 15 Mar 2018 Pooled analysis data presented in an Adamas Pharmaceuticals media release.
    • 12 Mar 2018 Results of pooled data from two ADS-5102 trials assessing efficacy and safety of amantadine extended release formulation for the treatment of levodopa induced dyskinesia (LID) in patients with Parkinson's disease (PD), were published in the CNS Drugs.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top